{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:55:56Z","timestamp":1783943756307,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["DRO (UHHK, 00179906)"],"award-info":[{"award-number":["DRO (UHHK, 00179906)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22\u201003\u201000370"],"award-info":[{"award-number":["NU22\u201003\u201000370"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Cooperatio"],"award-info":[{"award-number":["Cooperatio"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Idelalisib (idela), a phosphatidylinositol 3\u2010kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed\/refractory (R\/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R\u2010idela) versus ibrutinib have been conducted. Therefore, we performed a real\u2010world retrospective analysis of patients with R\/R CLL treated with R\u2010idela (<jats:italic>n<\/jats:italic>\u00a0=\u00a0171) or ibrutinib (<jats:italic>n<\/jats:italic>\u00a0=\u00a0244). The median age was 70 versus 69\u2009years, with a median of two previous lines. There was a trend towards higher tumour protein p53 (<jats:italic>TP53<\/jats:italic>) aberrations and complex karyotype in the R\u2010idela group (53% vs. 44%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.093; 57% vs. 46%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.083). The median progression\u2010free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0\u2009months; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); similarly to overall survival (OS; median 54.4 vs. 37.7\u2009months, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R\u2010idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R\u2010idela in patients with R\/R CLL treated in routine practice. The R\u2010idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative.<\/jats:p>","DOI":"10.1111\/bjh.18736","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T09:15:56Z","timestamp":1679908556000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: A real\u2010world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)"],"prefix":"10.1111","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-8218","authenticated-orcid":false,"given":"Martin","family":"\u0160pa\u010dek","sequence":"first","affiliation":[{"name":"1st Department of Medicine \u2013 Haematology, First Faculty of Medicine Charles University and General University Hospital in Prague  Nov\u00e9 M\u011bsto Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Smolej","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Haematology University Hospital and Charles University Faculty of Medicine  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160imkovi\u010d","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Haematology University Hospital and Charles University Faculty of Medicine  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Nekvindov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Ltd.  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatu\u0161e","family":"K\u0159\u00edstkov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Ltd.  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvona","family":"Brychtov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology University Hospital  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Panovsk\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology University Hospital  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislava","family":"Ma\u0161lejov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology University Hospital  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Bezd\u011bkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology University Hospital  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"\u00c9csiov\u00e1","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Haematology University Hospital and Charles University Faculty of Medicine  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Vod\u00e1rek","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Haematology University Hospital and Charles University Faculty of Medicine  Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zuchnick\u00e1","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Mih\u00e1lyov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava  Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Urbanov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Olomouc  Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-3841","authenticated-orcid":false,"given":"Peter","family":"Turcs\u00e1nyi","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Olomouc  Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lys\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology University Hospital Plze\u0148  Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nov\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Haematology, Third Faculty of Medicine University Hospital Kr\u00e1lovsk\u00e9 Vinohrady  Praha Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brejcha","sequence":"additional","affiliation":[{"name":"Hospital Agel  Nov\u00fd Ji\u010d\u00edn Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"L\u00edka\u0159ov\u00e1","sequence":"additional","affiliation":[{"name":"1st Department of Medicine \u2013 Haematology, First Faculty of Medicine Charles University and General University Hospital in Prague  Nov\u00e9 M\u011bsto Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-1268","authenticated-orcid":false,"given":"Prokop","family":"Vodi\u010dka","sequence":"additional","affiliation":[{"name":"1st Department of Medicine \u2013 Haematology, First Faculty of Medicine Charles University and General University Hospital in Prague  Nov\u00e9 M\u011bsto Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Baranov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Analyses, Ltd.  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"1st Department of Medicine \u2013 Haematology, First Faculty of Medicine Charles University and General University Hospital in Prague  Nov\u00e9 M\u011bsto Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology University Hospital  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Czech CLL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01935.x"},{"issue":"1","key":"e_1_2_9_9_1","first-page":"S11","article-title":"Differences in availability of targeted inhibitors and use of chemoimmunotherapy in the first\u2010line therapy of chronic lymphocytic leukemia. A European survey","volume":"62","author":"Smolej L","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17475"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2861"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13573"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_2_9_17_1","first-page":"3025","article-title":"Comparable efficacy of Idelalisib plus rituximab and Ibrutinib in relapsed\/refractory chronic lymphocytic leukemia: a retrospective case matched study of the polish adult leukemia group (PALG)","volume":"38","author":"Pu\u0142a B","year":"2018","journal-title":"Anticancer Res"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.04.007"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1312.1312"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31554"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004824"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16879"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17472"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T10:32:08Z","timestamp":1699612328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/bjh.18736"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18736","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"2022-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}